These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37948017)

  • 1. Role of Soluble Urokinase-Type Plasminogen Activator Receptor in Cardiovascular Disease.
    Ismail A; Hayek SS
    Curr Cardiol Rep; 2023 Dec; 25(12):1797-1810. PubMed ID: 37948017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. suPAR in cardiovascular disease.
    Montecillo J; Pirker T; Pemberton C; Chew-Harris J
    Adv Clin Chem; 2024; 121():89-131. PubMed ID: 38797545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.
    Hindy G; Tyrrell DJ; Vasbinder A; Wei C; Presswalla F; Wang H; Blakely P; Ozel AB; Graham S; Holton GH; Dowsett J; Fahed AC; Amadi KM; Erne GK; Tekmulla A; Ismail A; Launius C; Sotoodehnia N; Pankow JS; Thørner LW; Erikstrup C; Pedersen OB; Banasik K; Brunak S; Ullum H; Eugen-Olsen J; Ostrowski SR; ; Haas ME; Nielsen JB; Lotta LA; ; Engström G; Melander O; Orho-Melander M; Zhao L; Murthy VL; Pinsky DJ; Willer CJ; Heckbert SR; Reiser J; Goldstein DR; Desch KC; Hayek SS
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36194491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease.
    Goodchild TT; Li Z; Lefer DJ
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.
    Rasmussen LJH; Petersen JEV; Eugen-Olsen J
    Front Immunol; 2021; 12():780641. PubMed ID: 34925360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble urokinase-type plasminogen activator receptor (suPAR) is elevated in caregivers of patients with parkinsonism.
    Joyce J; Cabanas N; Pisharody R; Ouyang B; Patel R; Reiser J; Hall DA; Witek N
    Parkinsonism Relat Disord; 2022 Aug; 101():39-42. PubMed ID: 35780693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble Urokinase Plasminogen Activator Receptor Levels and Outcomes in Patients with Heart Failure.
    Hayek SS; Tahhan AS; Ko YA; Alkhoder A; Zheng S; Bhimani R; Hartsfield J; Kim J; Wilson P; Shaw L; Wei C; Reiser J; Quyyumi AA
    J Card Fail; 2023 Feb; 29(2):158-167. PubMed ID: 36122818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Urokinase Plasminogen Activator Receptor: Genetic Variation and Cardiovascular Disease Risk in Black Adults.
    Olson NC; Raffield LM; Moxley AH; Miller-Fleming TW; Auer PL; Franceschini N; Ngo D; Thornton TA; Lange EM; Li Y; Nickerson DA; Zakai NA; Gerszten RE; Cox NJ; Correa A; Mohlke KL; Reiner AP
    Circ Genom Precis Med; 2021 Dec; 14(6):e003421. PubMed ID: 34706549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor.
    Dowsett J; Ferkingstad E; Rasmussen LJH; Thørner LW; Magnússon MK; Sugden K; Thorleifsson G; Frigge M; Burgdorf KS; Ostrowski SR; Sørensen E; Erikstrup C; Pedersen OB; Hansen TF; Banasik K; Brunak S; ; Tragante V; Lund SH; Stefansdottir L; Gunnarson B; Poulton R; Arseneault L; Caspi A; Moffitt TE; Gudbjartsson D; Eugen-Olsen J; Stefánsson H; Stefánsson K; Ullum H
    Commun Biol; 2021 Jun; 4(1):655. PubMed ID: 34079037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble Urokinase Plasminogen Activator Receptor is Associated with Coronary Artery Calcification and Cardiovascular Disease in Patients Undergoing Hemodialysis.
    Wu W; Cui Y; Hu J; Liao R; Li S; Mo L; Xu L; Chen Y; Lian Z; Tian X; Li Z; Li R; Zhang L; Liang H; Ma J; Lin T; Feng Z; Dong W; Ke G; Ge P; Ye Z; Wang W; Zhang B; Shi W; Liang X; Liu S
    Kidney Blood Press Res; 2018; 43(3):664-672. PubMed ID: 29734173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
    Edsfeldt A; Nitulescu M; Grufman H; Grönberg C; Persson A; Nilsson M; Persson M; Björkbacka H; Gonçalves I
    Stroke; 2012 Dec; 43(12):3305-12. PubMed ID: 23150653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
    Persson M; Engström G; Björkbacka H; Hedblad B
    Atherosclerosis; 2012 Feb; 220(2):502-5. PubMed ID: 22119508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cadmium exposure is associated with soluble urokinase plasminogen activator receptor, a circulating marker of inflammation and future cardiovascular disease.
    Fagerberg B; Borné Y; Barregard L; Sallsten G; Forsgard N; Hedblad B; Persson M; Engström G
    Environ Res; 2017 Jan; 152():185-191. PubMed ID: 27792942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
    Sehestedt T; Lyngbæk S; Eugen-Olsen J; Jeppesen J; Andersen O; Hansen TW; Linneberg A; Jørgensen T; Haugaard SB; Olsen MH
    Atherosclerosis; 2011 May; 216(1):237-43. PubMed ID: 21354571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD.
    Böcskei RM; Benczúr B; Losonczy G; Illyés M; Cziráki A; Müller V; Bohács A; Bikov A
    Lung; 2019 Apr; 197(2):189-197. PubMed ID: 30820636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of soluble urokinase plasminogen activator receptor (suPAR) in patients with cancer: a review of the current literature.
    Paraskevas T; Mulita F; Michailides C; Verras GI; Liolis E; Oikonomou E; Perdikaris I; Perdikaris P; Bouchagier K; Panagiotopoulos I; Kasartzian DI; Filis D; Tchabashvili L; Spyropoulou D; Velissaris D
    Med Glas (Zenica); 2022 Aug; 19(2):. PubMed ID: 35924801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythematosus.
    Enocsson H; Wetterö J; Skogh T; Sjöwall C
    Transl Res; 2013 Nov; 162(5):287-96. PubMed ID: 23916811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.